{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:45:15Z","timestamp":1789026315408,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100014688","name":"Region Uppsala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016\u201000398"],"award-info":[{"award-number":["2016\u201000398"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002960","name":"V\u00e4sterbotten L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002960","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009228","name":"Region \u00d6rebro l\u00e4n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009228","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RIFUND\u2010MS was a 2\u2010year, rater\u2010blinded, 1:1 randomized controlled multicenter trial comparing DMF and RTX in relapsing\u2013remitting multiple sclerosis (RRMS). Serum samples for analysis of sNFL and sGFAP were collected at baseline and 0, 6, 12 and 24. Log\u2010transformed biomarker data were analyzed with linear mixed models, based on intention to treat (ITT), per protocol (PP) and accounting for therapy switches. Cox proportional hazards models were performed to evaluate progression outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 200 participants, 197 were analyzed. Based on ITT, sNfL decreased significantly in both arms from baseline to month 24; by 50.7% (CI 43.7%\u201356.8%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) with RTX, and by 46.4% (CI 38.6%\u201353.2%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) with DMF, no differences between treatments (global\n                      <jats:italic>p<\/jats:italic>\n                      \u2010value: ITT\u2009=\u20090.06; PP\u2009=\u20090.08; switch group\u2009=\u20090.15). In contrast, sGFAP remained stable in RTX (3.6% decrease; CI \u22127.8%\u201313.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.81) but decreased with DMF (18.4%; CI 8.5%\u201327.2%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Global analyses favored DMF (ITT\u2009=\u20090.02; PP\u2009=\u20090.004; switch group\u2009=\u20090.74). The risk of progression independent of relapse and MRI activity (PIRMA) was higher with RTX (HR 3.3, CI 1.1\u201310,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Both RTX and DMF reduced sNfL levels, consistent with suppression of acute inflammatory disease activity. However, only DMF was associated with a sustained reduction in sGFAP and a lower risk of non\u2010inflammatory disability progression. These findings suggest that DMF may exert additional effects on astrocyte\u2010related or compartmentalized CNS pathology beyond peripheral immune modulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acn3.70395","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:53:07Z","timestamp":1776055987000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dimethyl Fumarate, But Not Rituximab, Reduces Serum\n                    <scp>GFAP<\/scp>\n                    Levels and\n                    <scp>PIRMA<\/scp>\n                    in Relapsing\u2013Remitting\n                    <scp>MS<\/scp>"],"prefix":"10.1002","author":[{"given":"F.","family":"Shawket","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Karolinska Institutet Danderyd Hospital and Department of Neurology, Danderyd Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lycke","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Sahlgrenska Academy Gothenburg University  Gothenburg Sweden"},{"name":"Department of Neurology Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salzer","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences Ume\u00e5 University  Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"F.","family":"Piehl","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Department of Neurology Karolinska University Hospital, and Academic Specialist Center  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fink","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Department of Neurology Karolinska University Hospital, and Academic Specialist Center  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Karolinska Institutet Danderyd Hospital and Department of Neurology, Danderyd Hospital  Stockholm Sweden"},{"name":"Department of Neurology \u00d6rebro University  \u00d6rebro Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mellerg\u00e5rd","sequence":"additional","affiliation":[{"name":"Department of Neurology, and Department of Biomedical and Clinical Sciences Link\u00f6ping University  Link\u00f6ping Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Malmestr\u00f6m","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Physiology, Sahlgrenska Academy Gothenburg University  Gothenburg Sweden"},{"name":"Laboratory for Clinical Immunology Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Neurosciences Ume\u00e5 University  Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Erngren","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"al\u2010Grety","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Freyhult","sequence":"additional","affiliation":[{"name":"National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of Cell and Molecular Biology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kultima","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Burman","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Translational Neurology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-2220","authenticated-orcid":false,"given":"A.","family":"Svenningsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Karolinska Institutet Danderyd Hospital and Department of Neurology, Danderyd Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"issue":"2","key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological Mechanisms in Progressive Multiple Sclerosis","volume":"14","author":"Mahad D. H.","year":"2015","journal-title":"Lancet Neurology"},{"issue":"2","key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The Immunopathology of Multiple Sclerosis: An Overview","volume":"17","author":"Lassmann H.","year":"2007","journal-title":"Brain Pathology"},{"issue":"5","key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1084\/jem.91.5.499","article-title":"The Fibrous Structure of the Nerve Axon in Relation to the Localization of Neurotubules","volume":"91","author":"Schmitt F. O.","year":"1950","journal-title":"Journal of Experimental Medicine"},{"issue":"6","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/13524585211039104","article-title":"Exploring CSF Neurofilament Light as a Biomarker for MS in Clinical Practice; a Retrospective Registry\u2010Based Study","volume":"28","author":"Rosenstein I.","year":"2022","journal-title":"Multiple Sclerosis"},{"issue":"22","key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring Disease Activity in Multiple Sclerosis Using Serum Neurofilament Light Protein","volume":"89","author":"Novakova L.","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1023\/A:1007677003387","article-title":"Glial Fibrillary Acidic Protein: GFAP\u2010Thirty\u2010One Years (1969\u20102000)","volume":"25","author":"Eng L. F.","year":"2000","journal-title":"Neurochemical Research"},{"issue":"5","key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial Fibrillary Acidic Protein: A Potential Biomarker for Progression in Multiple Sclerosis","volume":"258","author":"Axelsson M.","year":"2011","journal-title":"Journal of Neurology"},{"issue":"3","key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"Meier S.","year":"2023","journal-title":"JAMA Neurology"},{"issue":"2","key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum Glial Fibrillary Acidic Protein and Disability Progression in Progressive Multiple Sclerosis","volume":"11","author":"Abdelhak A.","year":"2024","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"8","key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and Efficacy of Rituximab Versus Dimethyl Fumarate in Patients With Relapsing\u2010Remitting Multiple Sclerosis or Clinically Isolated Syndrome in Sweden: A Rater\u2010Blinded, Phase 3, Randomised Controlled Trial","volume":"21","author":"Svenningsson A.","year":"2022","journal-title":"Lancet Neurology"},{"issue":"20","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects","volume":"310","author":"World Medical A","year":"2013","journal-title":"Journal of the American Medical Association"},{"issue":"13","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest Package: Tests in Linear Mixed Effects Models. Journal of Statistical Software","volume":"82","author":"Kuznetsova A.","year":"2017","journal-title":"Journal of Statistical Software"},{"key":"e_1_2_9_14_1","unstructured":"R.Lenth \u201cEmmeans: Estimated Marginal Means Aka Least\u2010Squares Means \u201d(2024) https:\/\/cran.r\u2010project.org\/web\/packages\/emmeans\/index.html."},{"issue":"3","key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","article-title":"Neurofilament Protein in Cerebrospinal Fluid: A Potential Marker of Activity in Multiple Sclerosis","volume":"64","author":"Lycke J. N.","year":"1998","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"6","key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis","volume":"81","author":"Disanto G.","year":"2017","journal-title":"Annals of Neurology"},{"issue":"2","key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ane.12239","article-title":"Assessing Tissue Damage in Multiple Sclerosis: A Biomarker Approach","volume":"130","author":"Burman J.","year":"2014","journal-title":"Acta Neurologica Scandinavica"},{"issue":"3","key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum Neurofilament Light Chain for Individual Prognostication of Disease Activity in People With Multiple Sclerosis: A Retrospective Modelling and Validation Study","volume":"21","author":"Benkert P.","year":"2022","journal-title":"Lancet Neurology"},{"issue":"1","key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ana.22247","article-title":"Axonal Damage in Relapsing Multiple Sclerosis Is Markedly Reduced by Natalizumab","volume":"6","author":"Gunnarsson M.","year":"2011","journal-title":"Annals of Neurology"},{"issue":"6","key":"e_1_2_9_20_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser S. L.","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1111\/ene.15009","article-title":"Plasma Neurofilament Light Chain Concentrations as a Biomarker of Clinical and Radiologic Outcomes in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials","volume":"28","author":"Harris S.","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"4","key":"e_1_2_9_22_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","article-title":"Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis","volume":"81","author":"Cross A. H.","year":"2024","journal-title":"JAMA Neurology"},{"issue":"5","key":"e_1_2_9_23_1","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/awae035","article-title":"Serum GFAP Levels Correlate With Astrocyte Reactivity, Post\u2010Mortem Brain Atrophy and Neurofibrillary Tangles","volume":"147","author":"Sanchez\u2010Juan P.","year":"2024","journal-title":"Brain"},{"issue":"4","key":"e_1_2_9_24_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001164","article-title":"Role of Chitinase 3\u2010Like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta\u2010Analysis","volume":"9","author":"Floro S.","year":"2022","journal-title":"Neurology Neuroimmunology and Neuroinflammation"},{"issue":"10","key":"e_1_2_9_25_1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585231188625","article-title":"Serum Glial Fibrillary Acidic Protein in Natalizumab\u2010Treated Relapsing\u2010Remitting Multiple Sclerosis: An Alternative to Neurofilament Light","volume":"29","author":"Wessels M. H.","year":"2023","journal-title":"Multiple Sclerosis"},{"issue":"7","key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1007\/s00415-024-12389-y","article-title":"Association of Serum Glial Fibrillary Acidic Protein With Progression Independent of Relapse Activity in Multiple Sclerosis","volume":"271","author":"Rosenstein I.","year":"2024","journal-title":"Journal of Neurology"},{"key":"e_1_2_9_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1265354","article-title":"A Five\u2010Year Observational Prospective Mono\u2010Center Study of the Efficacy of Alemtuzumab in a Real\u2010World Cohort of Patients With Multiple Sclerosis","volume":"14","author":"Sandgren S.","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"e_1_2_9_28_1","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70222","article-title":"Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials","volume":"32","author":"Harris S.","year":"2025","journal-title":"European Journal of Neurology"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00278","article-title":"Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases","volume":"7","author":"Al\u2010Jaderi Z.","year":"2016","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab Therapy for CNS Lymphomas: Targeting the Leptomeningeal Compartment","volume":"101","author":"Rubenstein J. L.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-7-30","article-title":"Dimethylfumarate Inhibits Microglial and Astrocytic Inflammation by Suppressing the Synthesis of Nitric Oxide, IL\u20101beta, TNF\u2010Alpha and IL\u20106 in an In\u2010Vitro Model of Brain Inflammation","volume":"7","author":"Wilms H.","year":"2010","journal-title":"Journal of Neuroinflammation"},{"issue":"6","key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/acn3.414","article-title":"Effects of Fumarates on Inflammatory Human Astrocyte Responses and Oligodendrocyte Differentiation","volume":"4","author":"Galloway D. A.","year":"2017","journal-title":"Annals of Clinical Translational Neurology"},{"issue":"4","key":"e_1_2_9_33_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040857","article-title":"Dimethyl Fumarate Suppresses Demyelination and Axonal Loss Through Reduction in Pro\u2010Inflammatory Macrophage\u2010Induced Reactive Astrocytes and Complement C3 Deposition","volume":"10","author":"Yadav S. K.","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2025.111356","article-title":"The Janus Face of Astrocytes in Multiple Sclerosis: Balancing Protection and Pathology","volume":"226","author":"Abulaban A. A.","year":"2025","journal-title":"Brain Research Bulletin"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:53:20Z","timestamp":1776056000000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":33,"alternative-id":["10.1002\/acn3.70395"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70395","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acn3.70395"}}